Compare Stocks: PRQR, DRUG, PHAR, and RIGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$79.33	$70.32	$34.19 ▼ $123.75	$772.04M	-5.27	222,278 shs	156,403 shs
PHAR Pharming Group	$10.85 -0.9%	$12.74	$9.62 ▼ $21.34	$767.96M	-0.01	10,186 shs	6,391 shs
PRQR ProQR Therapeutics	$1.88	$1.70	$1.33 ▼ $3.10	$197.55M	0.07	848,277 shs	558,445 shs
RIGL Rigel Pharmaceuticals	$40.17	$36.87	$24.95 ▼ $52.24	$743.15M	1.16	327,414 shs	315,509 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	0.00%	+8.29%	+1.91%	-8.34%	+104.35%
PHAR Pharming Group	0.00%	+7.64%	-21.72%	-15.56%	-17.99%
PRQR ProQR Therapeutics	0.00%	+9.01%	+8.38%	+16.46%	-13.59%
RIGL Rigel Pharmaceuticals	0.00%	+9.13%	-5.59%	+53.32%	+26.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$79.33	$70.32	$34.19 ▼ $123.75	$772.04M	-5.27	222,278 shs	156,403 shs
PHAR Pharming Group	$10.85 -0.9%	$12.74	$9.62 ▼ $21.34	$767.96M	-0.01	10,186 shs	6,391 shs
PRQR ProQR Therapeutics	$1.88	$1.70	$1.33 ▼ $3.10	$197.55M	0.07	848,277 shs	558,445 shs
RIGL Rigel Pharmaceuticals	$40.17	$36.87	$24.95 ▼ $52.24	$743.15M	1.16	327,414 shs	315,509 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	0.00%	+8.29%	+1.91%	-8.34%	+104.35%
PHAR Pharming Group	0.00%	+7.64%	-21.72%	-15.56%	-17.99%
PRQR ProQR Therapeutics	0.00%	+9.01%	+8.38%	+16.46%	-13.59%
RIGL Rigel Pharmaceuticals	0.00%	+9.13%	-5.59%	+53.32%	+26.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	3.14	Buy	$143.83	81.31% Upside
PHAR Pharming Group	2.20	Hold	$38.67	256.37% Upside
PRQR ProQR Therapeutics	2.50	Moderate Buy	$7.33	291.11% Upside
RIGL Rigel Pharmaceuticals	2.50	Moderate Buy	$54.50	35.67% Upside

Current Analyst Ratings Breakdown

Latest PRQR, DRUG, PHAR, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	RIGL Rigel Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/21/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
6/26/2026	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $3.00
6/26/2026	PRQR ProQR Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$11.00 ➝ $10.00
6/23/2026	PRQR ProQR Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	PRQR ProQR Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
PHAR Pharming Group	$376.13M	2.04	$0.20 per share	54.60	$3.95 per share	2.75
PRQR ProQR Therapeutics	$17.99M	10.98	N/A	N/A	$0.53 per share	3.54
RIGL Rigel Pharmaceuticals	$294.28M	2.53	$6.74 per share	5.96	$21.57 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$8.74M	-$2.44	N/A	N/A	N/A	N/A	-20.58%	-20.25%	8/13/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	90.42	36.17	N/A	2.51%	3.40%	1.90%	N/A
PRQR ProQR Therapeutics	-$47.73M	-$0.50	N/A	N/A	N/A	-331.33%	-84.87%	-37.78%	N/A
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.46	11.04	N/A	116.30%	22.95%	17.19%	N/A

Latest PRQR, DRUG, PHAR, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2831	N/A	N/A	N/A	N/A	N/A
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	$90.20 million
5/20/2026	Q2 2026	DRUG Bright Minds Biosciences	-$0.8633	-$0.80	+$0.0633	-$0.80	N/A	N/A
5/12/2026	Q1 2026	PRQR ProQR Therapeutics	-$0.15	-$0.15	N/A	-$0.15	$5.19 million	$2.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	81.47	81.47
PHAR Pharming Group	0.34	3.01	2.31
PRQR ProQR Therapeutics	N/A	2.48	2.48
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
PHAR Pharming Group	0.03%
PRQR ProQR Therapeutics	32.65%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
PHAR Pharming Group	2.07%
PRQR ProQR Therapeutics	8.40%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	N/A	9.73 million	5.58 million	Not Optionable
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable
PRQR ProQR Therapeutics	180	105.36 million	96.51 million	Optionable
RIGL Rigel Pharmaceuticals	160	18.50 million	16.57 million	Optionable

PRQR, DRUG, PHAR, and RIGL Headlines

Recent News About These Companies

HC Wainwright Brokers Reduce Earnings Estimates for RIGL

August 9 at 1:14 AM | americanbankingnews.com

Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL

August 8 at 5:03 AM | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for RIGL Earnings

August 8 at 2:13 AM | americanbankingnews.com

HC Wainwright Issues Pessimistic Estimate for RIGL Earnings

August 7 at 6:11 AM | marketbeat.com

Pacer Advisors Inc. Purchases 48,882 Shares of Rigel Pharmaceuticals, Inc. $RIGL

August 7 at 5:19 AM | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up After Better-Than-Expected Earnings

August 7 at 1:41 AM | americanbankingnews.com

HC Wainwright Issues Pessimistic Forecast for RIGL Earnings

August 6, 2026 | marketbeat.com

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 6, 2026 | marketbeat.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Earnings Beat

August 5, 2026 | marketbeat.com

Rigel: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 4, 2026 | seekingalpha.com

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Rigel Pharmaceuticals Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Estimates By $0.79 EPS

August 4, 2026 | marketbeat.com

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

August 4, 2026 | zacks.com

Rigel Reports Second Quarter 2026 Financial Results

August 4, 2026 | prnewswire.com

Arrowstreet Capital Limited Partnership Has $4.53 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGL

August 4, 2026 | marketbeat.com

Renaissance Technologies LLC Sells 200,568 Shares of Rigel Pharmaceuticals, Inc. $RIGL

August 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRQR, DRUG, PHAR, and RIGL Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

$79.33 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$79.00 -0.33 (-0.41%)

As of 08/7/2026 07:34 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Pharming Group NASDAQ:PHAR

$10.85 -0.10 (-0.91%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$10.85 0.00 (0.00%)

As of 08/7/2026 07:34 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NASDAQ:PRQR

$1.88 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.88 0.00 (0.00%)

As of 08/7/2026 07:34 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Rigel Pharmaceuticals NASDAQ:RIGL

$40.17 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$40.26 +0.09 (+0.21%)

As of 08/7/2026 07:34 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRQR, DRUG, PHAR, and RIGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRQR, DRUG, PHAR, and RIGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRQR, DRUG, PHAR, and RIGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRQR, DRUG, PHAR, and RIGL Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

Pharming Group NASDAQ:PHAR

ProQR Therapeutics NASDAQ:PRQR

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRQR, DRUG, PHAR, and RIGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRQR, DRUG, PHAR, and RIGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRQR, DRUG, PHAR, and RIGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRQR, DRUG, PHAR, and RIGL Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

Pharming Group NASDAQ:PHAR

ProQR Therapeutics NASDAQ:PRQR

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools